AG˹ٷ

STOCK TITAN

[SCHEDULE 13G/A] Forrester Research Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Omeros Corporation (OMER) filed a Form 4 disclosing that non-employee director Dr. Leroy E. Hood received an annual stock-option grant for 15,000 shares on 27 Jun 2025. The option carries a $3.20 exercise price, a 10-year term expiring 27 Jun 2035, and will vest in full the day before the 2026 annual shareholder meeting provided he remains a director. No open-market purchases or sales of common stock were reported, and Table I shows no change in non-derivative share ownership. The filing reflects routine director compensation and represents a negligible portion of Omeros� total shares outstanding, implying minimal immediate dilution or market impact.

Omeros Corporation (OMER) ha presentato un Modulo 4 comunicando che il direttore non dipendente Dr. Leroy E. Hood ha ricevuto una concessione annuale di opzioni su azioni per 15.000 titoli il 27 giugno 2025. L'opzione ha un prezzo di esercizio di 3,20 $, una durata di 10 anni con scadenza il 27 giugno 2035, e maturerà completamente il giorno prima dell'assemblea annuale degli azionisti del 2026, a condizione che rimanga direttore. Non sono stati segnalati acquisti o vendite di azioni ordinarie sul mercato aperto, e la Tabella I mostra nessuna variazione nella proprietà delle azioni non derivate. La comunicazione riflette una retribuzione ordinaria per i direttori e rappresenta una porzione trascurabile del totale delle azioni in circolazione di Omeros, implicando un impatto minimo immediato in termini di diluizione o sul mercato.

Omeros Corporation (OMER) presentó un Formulario 4 revelando que el director externo Dr. Leroy E. Hood recibió una concesión anual de opciones sobre acciones por 15,000 títulos el 27 de junio de 2025. La opción tiene un precio de ejercicio de 3,20 $, un plazo de 10 años que vence el 27 de junio de 2035, y se consolidará en su totalidad el día antes de la junta anual de accionistas de 2026, siempre que continúe siendo director. No se reportaron compras o ventas en el mercado abierto de acciones ordinarias, y la Tabla I no muestra cambios en la propiedad de acciones no derivadas. La presentación refleja una compensación habitual para directores y representa una porción insignificante del total de acciones en circulación de Omeros, lo que implica un impacto inmediato mínimo en dilución o en el mercado.

Omeros Corporation (OMER)� 양식 4� 제출하여 비임� 이사� Dr. Leroy E. Hood가 2025� 6� 27일에 15,000주에 대� 연간 스톡옵션 부�� 받았음을 공개했습니다. � 옵션은 행사가격이 3.20달러이며, 10� 만기(2035� 6� 27� 만료)이고, 2026� 연례 주주총회 전날 전액 베스�(권리 확정)됩니�. �, 그가 이사직을 유지하는 경우� 한합니다. 보통� 공개시장 매수 또는 매도� 보고되지 않았으며, � I에는 비파� 주식 보유 변동이 없습니다. 이번 제출은 이사 보수� 일환으로, Omeros� � 발행 주식 � 미미� 비율� 불과하여 즉각적인 희석 효과� 시장 영향은 거의 없음� 의미합니�.

Omeros Corporation (OMER) a déposé un formulaire 4 révélant que le directeur non salarié Dr Leroy E. Hood a reçu une attribution annuelle d’options sur actions pour 15 000 titres le 27 juin 2025. L’option comporte un prix d’exercice de 3,20 $, une durée de 10 ans expirant le 27 juin 2035, et sera totalement acquise la veille de l’assemblée annuelle des actionnaires de 2026, à condition qu’il reste directeur. Aucun achat ou vente d’actions ordinaires sur le marché libre n’a été signalé, et le tableau I ne montre aucun changement dans la détention d’actions non dérivées. Ce dépôt reflète une rémunération habituelle des administrateurs et représente une part négligeable du total des actions en circulation d’Omeros, impliquant un impact immédiat minimal en termes de dilution ou de marché.

Omeros Corporation (OMER) reichte ein Formular 4 ein, das offenlegt, dass der nicht geschäftsführende Direktor Dr. Leroy E. Hood am 27. Juni 2025 eine jährliche Aktienoptionszuteilung über 15.000 Aktien erhielt. Die Option hat einen Ausübungspreis von 3,20 $, eine Laufzeit von 10 Jahren bis zum 27. Juni 2035 und wird am Tag vor der jährlichen Hauptversammlung 2026 vollständig unverfallbar, vorausgesetzt, er bleibt Direktor. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine Änderung im Besitz nicht-derivativer Aktien. Die Meldung spiegelt eine übliche Vergütung für Direktoren wider und stellt einen vernachlässigbaren Anteil der insgesamt ausstehenden Aktien von Omeros dar, was auf eine minimale unmittelbare Verwässerung oder Markteinwirkung hinweist.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine annual option grant; neutral impact on valuation or sentiment.

This Form 4 records the standard 15 k option award for non-employee directors under Omeros� compensation policy. The $3.20 strike aligns with prevailing market levels, so the grant is neither a bargain purchase nor a bullish signal. With tens of millions of shares outstanding, 15 k options are immaterial for dilution and unlikely to influence trading dynamics. Because no open-market transactions occurred, the filing offers limited insight into insider conviction. I view the disclosure as administrative and not materially impactful for investors.

Omeros Corporation (OMER) ha presentato un Modulo 4 comunicando che il direttore non dipendente Dr. Leroy E. Hood ha ricevuto una concessione annuale di opzioni su azioni per 15.000 titoli il 27 giugno 2025. L'opzione ha un prezzo di esercizio di 3,20 $, una durata di 10 anni con scadenza il 27 giugno 2035, e maturerà completamente il giorno prima dell'assemblea annuale degli azionisti del 2026, a condizione che rimanga direttore. Non sono stati segnalati acquisti o vendite di azioni ordinarie sul mercato aperto, e la Tabella I mostra nessuna variazione nella proprietà delle azioni non derivate. La comunicazione riflette una retribuzione ordinaria per i direttori e rappresenta una porzione trascurabile del totale delle azioni in circolazione di Omeros, implicando un impatto minimo immediato in termini di diluizione o sul mercato.

Omeros Corporation (OMER) presentó un Formulario 4 revelando que el director externo Dr. Leroy E. Hood recibió una concesión anual de opciones sobre acciones por 15,000 títulos el 27 de junio de 2025. La opción tiene un precio de ejercicio de 3,20 $, un plazo de 10 años que vence el 27 de junio de 2035, y se consolidará en su totalidad el día antes de la junta anual de accionistas de 2026, siempre que continúe siendo director. No se reportaron compras o ventas en el mercado abierto de acciones ordinarias, y la Tabla I no muestra cambios en la propiedad de acciones no derivadas. La presentación refleja una compensación habitual para directores y representa una porción insignificante del total de acciones en circulación de Omeros, lo que implica un impacto inmediato mínimo en dilución o en el mercado.

Omeros Corporation (OMER)� 양식 4� 제출하여 비임� 이사� Dr. Leroy E. Hood가 2025� 6� 27일에 15,000주에 대� 연간 스톡옵션 부�� 받았음을 공개했습니다. � 옵션은 행사가격이 3.20달러이며, 10� 만기(2035� 6� 27� 만료)이고, 2026� 연례 주주총회 전날 전액 베스�(권리 확정)됩니�. �, 그가 이사직을 유지하는 경우� 한합니다. 보통� 공개시장 매수 또는 매도� 보고되지 않았으며, � I에는 비파� 주식 보유 변동이 없습니다. 이번 제출은 이사 보수� 일환으로, Omeros� � 발행 주식 � 미미� 비율� 불과하여 즉각적인 희석 효과� 시장 영향은 거의 없음� 의미합니�.

Omeros Corporation (OMER) a déposé un formulaire 4 révélant que le directeur non salarié Dr Leroy E. Hood a reçu une attribution annuelle d’options sur actions pour 15 000 titres le 27 juin 2025. L’option comporte un prix d’exercice de 3,20 $, une durée de 10 ans expirant le 27 juin 2035, et sera totalement acquise la veille de l’assemblée annuelle des actionnaires de 2026, à condition qu’il reste directeur. Aucun achat ou vente d’actions ordinaires sur le marché libre n’a été signalé, et le tableau I ne montre aucun changement dans la détention d’actions non dérivées. Ce dépôt reflète une rémunération habituelle des administrateurs et représente une part négligeable du total des actions en circulation d’Omeros, impliquant un impact immédiat minimal en termes de dilution ou de marché.

Omeros Corporation (OMER) reichte ein Formular 4 ein, das offenlegt, dass der nicht geschäftsführende Direktor Dr. Leroy E. Hood am 27. Juni 2025 eine jährliche Aktienoptionszuteilung über 15.000 Aktien erhielt. Die Option hat einen Ausübungspreis von 3,20 $, eine Laufzeit von 10 Jahren bis zum 27. Juni 2035 und wird am Tag vor der jährlichen Hauptversammlung 2026 vollständig unverfallbar, vorausgesetzt, er bleibt Direktor. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine Änderung im Besitz nicht-derivativer Aktien. Die Meldung spiegelt eine übliche Vergütung für Direktoren wider und stellt einen vernachlässigbaren Anteil der insgesamt ausstehenden Aktien von Omeros dar, was auf eine minimale unmittelbare Verwässerung oder Markteinwirkung hinweist.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Comment relating to row 5: Consists of 6,070,862 shares held by Mr. Colony, individually. Comment relating to row 6: Consists of 1,580 shares owned by Mr. Colony's wife. Comment relating to row 7: Consists of: (1) 15,935 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 45 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; (2) 42,034 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 46 of which Mr. Colony is a trustee and has sole dispositive power; (3) 250,000 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 47 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; (4) 500,000 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 48 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; (5) 500,000 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 49 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; and (6) 6,070,862 shares held by Mr. Colony, individually. Comment relating to row 8: Consists of 1,580 shares owned by Mr. Colony's wife. Comment relating to row 9: Consists of: (1) 15,935 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 45 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; (2) 42,034 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 46 of which Mr. Colony is a trustee and has sole dispositive power; (3) 250,000 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 47 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; (4) 500,000 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 48 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; (5) 500,000 shares held by The George F. Colony 2024 Grantor Retained Annuity Trust No. 49 of which Mr. Colony is a trustee and has sole dispositive power and voting power is vested in the 3 other trustees; (6) 1,580 shares owned by Mr. Colony's wife; and (7) 6,070,862 shares held by Mr. Colony, individually. Comment relating to row 11: Based on 19,063,000 shares of common stock of the Issuer disclosed by the Issuer as outstanding as of May 5, 2025.


SCHEDULE 13G



George F. Colony
Signature:Ryan Darrah
Name/Title:Attorney-in-fact for George F. Colony
Date:07/01/2025
Forrester Resh Inc

NASDAQ:FORR

FORR Rankings

FORR Latest News

FORR Stock Data

184.15M
11.34M
40.24%
54.5%
0.83%
Consulting Services
Services-engineering, Accounting, Research, Management
United States
CAMBRIDGE